Interfractional robustness of scanning carbon ion radiotherapy for prostate cancer: An analysis based on dose distribution from daily in‐room CT images

Tsuchida, Keisuke; Minohara, Shinichi; Kusano, Yohsuke; Kano, Kio; Anno, Wataru; Takakusagi, Yosuke; Mizoguchi, Nobutaka; Serizawa, Itsuko; Yoshida, Daisaku; Imura, Koh; Takayama, Yoshiki; Kamada, Tadashi; Katoh, Hiroyuki; Ohno, Tatsuya

doi:10.1002/acm2.13275

Cited by 7 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Variations in the reproducibility of the dose distribution in actual treatment sessions in CIRT have been reported to be caused by variations in organ position, body shape and other variables [ 46 , 47 ]. However, reports of intra- and inter-fractional errors in CIRT for cervical cancer are scarce.…”

Section: Discussionmentioning

confidence: 99%

Preliminary result of combined treatment with scanning carbon-ion radiotherapy and image-guided brachytherapy for locally advanced cervical adenocarcinoma

Tsuchida,

Yoshida,

Shima

et al. 2024

Journal of Radiation Research

Self Cite

View full text Add to dashboard Cite

Although there is growing evidence of the efficacy of carbon-ion radiotherapy (CIRT) for locally advanced cervical adenocarcinoma, reports on combined treatment with CIRT and image-guided brachytherapy (IGBT) are scarce. We retrospectively analyzed patients with International Federation of Gynecology and Obstetrics (2008) stage II–IVA locally advanced cervical adenocarcinoma who received combined scanning CIRT (sCIRT) and IGBT between April 2019 and March 2022. sCIRT consisted of whole-pelvic irradiation with 36 Gy (relative biological effectiveness [RBE]) in 12 fractions and subsequent local boost irradiation with 19.2 Gy (RBE) in 4 fractions. Three sessions of IGBT were administered after completion of sCIRT. Concurrent chemotherapy using weekly cisplatin (40 mg/m2/week) was also administered. Efficacy, toxicity and dose–volume parameters were analyzed. Fifteen patients were included in the analysis. The median follow-up period was 25 months. The 2-year overall survival, progression-free survival and local control rates were 92.3% (95% confidence interval [CI] = 77.8–100%), 52.5% (95% CI = 26.9–78.1%) and 84.8% (95% CI = 65.2–100%), respectively. Neither severe acute toxicity necessitating treatment cessation nor grade 3 or higher late toxicity were observed. The sigmoid D2cm3 of the patient who developed grade 2 late sigmoid hemorrhage was 65.6 Gy, which exceeded the standard deviation and target dose. The combination of sCIRT and IGBT for locally advanced cervical adenocarcinoma showed acceptable efficacy and safety. Further large-scale and long-term studies are warranted to confirm the efficacy and safety of this treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Preliminary result of combined treatment with scanning carbon-ion radiotherapy and image-guided brachytherapy for locally advanced cervical adenocarcinoma

Tsuchida,

Yoshida,

Shima

et al. 2024

Journal of Radiation Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are several limitations to this study, including the small number of patients, the short observation period, inclusion of a single center, and the retrospective nature of the study. In addition, based on a study of the robustness of prostate cancer from our institution, a total of three in-room CTs were performed during sCIRT [30]. Therefore, the dose distribution in each treatment session could not be accurately evaluated.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Safety for Scanning Carbon-Ion Radiotherapy in Hemodialysis Patients With Prostate Cancer

Takakusagi

Suga

Kusano

et al. 2022

Cureus

Self Cite

View full text Add to dashboard Cite

Background/AimThe efficacy and safety of carbon-ion radiotherapy (CIRT) for prostate cancer have already been demonstrated. The number of hemodialysis (HD) patients is increasing. Although the toxicity of CIRT in HD patients may be more severe, it has been insufficiently investigated. Therefore, we retrospectively analyzed the safety of CIRT for HD patients with prostate cancer in the present study. Materials and methodsFive HD patients with prostate cancer who underwent CIRT at the Kanagawa Cancer Center during November 2015-2020 were included in this study. CIRT was delivered by the raster scanning method (sCIRT). Adverse events were assessed using the Common Terminology Criteria for Adverse Events version 5.0. The dose-volume histogram (DVH) parameters of the target volume and normal organs were evaluated between initial planning computed tomography (CT) and in-room CT images. ResultsIn the acute phase, Grade 1 genitourinary toxicity was recorded in one patient. In the late phase, Grade 1 genitourinary toxicity was recorded in two patients. No gastrointestinal toxicities were noted during the follow-up period. In-room CT analysis revealed no significant differences among all DVH parameters of the target volume and normal organs when compared with the treatment plan dose. ConclusionsThe safety of sCIRT for prostate cancer in HD patients was investigated in the present study. In-room CT analysis suggested the robustness of the treatment plan. According to the present results, sCIRT for prostate cancer can be safely performed in HD patients.

show abstract

Assessing the robustness of dose distributions in carbon ion prostate radiotherapy using a fast dose evaluation system

Tsubouchi,

Shiomi,

Suzuki

et al. 2024

J Applied Clin Med Phys

View full text Add to dashboard Cite

PurposeWe developed a software program for swiftly calculating dose distributions for carbon ion beams. This study aims to evaluate the accuracy of dose calculations using this software and assess the robustness of dose distribution in treating prostate cancer.MethodsAt the Osaka Heavy Ion Therapy Center, markers are inserted into the prostate gland and used for position verification. To account for geometric changes along the beam path due to marker translation, a beam‐specific planning target volume (bsPTV) is set for each beam. To validate the accuracy of the dose calculations using the developed software, dose distributions for prostate and sarcoma cases were calculated and compared with the treatment planning system. To assess the robustness of the dose distribution, position verification data from 346 cases were utilized to reproduce dose distributions for three matching methods: bone matching, widely adopted in most particle therapy centers; marker translation, which involves direct translation to markers without bone matching; and marker translation after bone matching. The coverage of the target (D99 of clinical target volume (CTV)) was assessed to evaluate the robustness of the dose distribution. Additionally, statistical analyses were conducted for the dose distributions of each matching method.ResultsThe dose calculation for a single condition can be completed very quickly. Statistical analysis revealed significant differences among dose distributions considering the three matching methods. When irradiation was performed with bone matching only, the D99 was reduced by more than 10% in approximately 7.5% of cases, making it as the poorest among the three matching methods. However, there was no significant reduction in target coverage with the other two methods.ConclusionWe have demonstrated the accuracy of the developed software for rapidly calculating dose distributions for carbon ion beams and confirmed the robustness of the dose distributions based on the bsPTV.

show abstract

Interfractional robustness of scanning carbon ion radiotherapy for prostate cancer: An analysis based on dose distribution from daily in‐room CT images

Cited by 7 publications

References 34 publications

Preliminary result of combined treatment with scanning carbon-ion radiotherapy and image-guided brachytherapy for locally advanced cervical adenocarcinoma

Preliminary result of combined treatment with scanning carbon-ion radiotherapy and image-guided brachytherapy for locally advanced cervical adenocarcinoma

Evaluation of Safety for Scanning Carbon-Ion Radiotherapy in Hemodialysis Patients With Prostate Cancer

Assessing the robustness of dose distributions in carbon ion prostate radiotherapy using a fast dose evaluation system

Contact Info

Product

Resources

About